Advances in proton therapy in lung cancer

Ther Adv Respir Dis. 2018 Jan-Dec:12:1753466618783878. doi: 10.1177/1753466618783878.

Abstract

Lung cancer remains the leading cause of cancer deaths in the United States (US) and worldwide. Radiation therapy is a mainstay in the treatment of locally advanced non-small cell lung cancer (NSCLC) and serves as an excellent alternative for early stage patients who are medically inoperable or who decline surgery. Proton therapy has been shown to offer a significant dosimetric advantage in NSCLC patients over photon therapy, with a decrease in dose to vital organs at risk (OARs) including the heart, lungs and esophagus. This in turn, can lead to a decrease in acute and late toxicities in a population already predisposed to lung and cardiac injury. Here, we present a review on proton treatment techniques, studies, clinical outcomes and toxicities associated with treating both early stage and locally advanced NSCLC.

Keywords: non-small cell lung cancer; pencil beam scanning; proton therapy; radiation therapy; toxicities.

Publication types

  • Review

MeSH terms

  • Animals
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Humans
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / radiotherapy*
  • Neoplasm Staging
  • Proton Therapy* / adverse effects
  • Proton Therapy* / mortality
  • Risk Factors
  • Treatment Outcome